Advertisement

Is the Catalytic Activity of Bence Jones Proteins an Autoimmune Effector Mechanism in Multiple Myeloma?

  • Hyogo Sinohara
  • Kinji Matsuura
Part of the Contemporary Immunology book series (CONTIM)

Abstract

On Friday, October 30, 1845, W. MacIntire, physician to the Metropolitan Convalescent Institution and to the Western General Dispensary, St. Marylebone, was called to see a patient who had been treated by T. Watson for several months (1,2). Since the patient had a history of edema, Maclntire examined the urine and noted the peculiar physical properties of the urinary protein (precipitation with heating at 40–60°C, disappearance with boiling, and reappearance with cooling). He wrote: “I was at first inclined to think that some mistake had occurred, but on repeated trials with other specimens, and closely watching their course, the results were always found to be the same” (2). Watson had evidently not examined the urine when the patient had been under his care, but was present when Maclntire performed urinalysis. In those days, it was customary for the specialist services to be provided by practicing physicians and surgeons. Urine specimens were sent to Henry Bence Jones, physician to St. George’s Hospital and professor of forensic medicine of the Medical College associated with the Hospital. Jones was then 31 yr old, but had already established a reputation as a chemical pathologist. He confirmed the Maclntire results and examined the protein in some detail. The patient died six weeks later, and an autopsy was performed by Shaw, surgeon to the Middlesex Hospital, in the presence of Watson, Jones, Ridge, and Maclntire, none of whom thought that the peculiar urinary protein was related to the disease, mollities ossium, later called multiple myeloma (2).

Keywords

Multiple Myeloma Light Chain Free Light Chain Catalytic Antibody Urinary Trypsin Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clamp, J. R. (1967) Some aspects of the first recorded case of multiple myeloma. Lancet 2, 1354–1356.PubMedCrossRefGoogle Scholar
  2. 2.
    MacIntire, W. (1850) Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med. Chir. Trans. 33, 211–232.Google Scholar
  3. 3.
    Jones, B. H. (1847) Papers on chemical pathology; prefaced by the Gulstonian Lectures, read at the Royal College of Physicians, 1846. Lancet 2, 88–92.CrossRefGoogle Scholar
  4. 4.
    Peeters, H. (chairman) and 21 other participants (1961) Round table conference: New methods and recent results in protide chemistry. Protides Biol. Fluids 9, 359–370.Google Scholar
  5. 5.
    Migita, S. (1965) The story of Bence Jones protein (in Japanese). Kyudai Iho 35, 205–209.Google Scholar
  6. 6.
    Edelman, G. M. and Gaily, J. A. (1962) The nature of Bence Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal γ-globu-lins. J. Exp. Med. 116, 207–227.PubMedCrossRefGoogle Scholar
  7. 7.
    Erhan, S., and Greller, L. D. (1974) Do immunoglobulins have proteolytic activity? Nature 251, 353–355.PubMedCrossRefGoogle Scholar
  8. 8.
    Mei, S., Mody, R., Ekulund, S. H., and Paul, S. (1991) Vasoactive intestinal peptide hydrolysis by antibody light chains. J. Biol. Chem. 266, 15571–15574.PubMedGoogle Scholar
  9. 9.
    Gao, Q.-S., Sun, M., Tyutyukova, S., Webster, D., Rees, A., Tranibtabim A., et al. (1994) Molecular cloning of a proteolytic antibody light chain. J. Biol. Chem. 269, 32389–32393.PubMedGoogle Scholar
  10. 10.
    Sun, M., Gao, Q.-S., Li, L., and Paul, S. (1994) Proteolytic activity of an antibody light chain. J. Immunol. 153, 5121–5126.PubMedGoogle Scholar
  11. 11.
    Paul, S., Li, L., Kalga, R., Wilkins-Stevens, P., Stevens, F. J., and Solomon, A. (1995) Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270, 15257–15262.PubMedCrossRefGoogle Scholar
  12. 12.
    Matsuura, K., Yamamoto, K., and Sinohara, H. (1994) Amidase activity of human Bence Jones proteins. Biochem. Biophys. Res. Commun. 204, 57–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Matsuura, K. and Sinohara, H. (1996) Catalytic cleavage of vasopressin by human Bence Jones proteins at the arginylglycinamide bond. Biol. Chem. 377, 587–589.PubMedGoogle Scholar
  14. 14.
    Selby, P. and Gore, M. (1995) Myeloma and other plasma cell malignancies, in Oxford Textbook of Oncology (Peckham, M., Pinego, H., and Veronesi, U., eds.) vol. 1, pp. 1852–1878.Google Scholar
  15. 15.
    Buxbaum, J. (1992) Mechanisms of disease: Monoclonal immunoglobulin deposition. Hematol. Oncol. Clin. N. Am. 6, 323–346.Google Scholar
  16. 16.
    Pascali, E. and Pezzoli, A. (1988) The clinical spectrum of pure Bence Jones pro-teinuria. Cancer 62, 2408–2415.PubMedCrossRefGoogle Scholar
  17. 17.
    Lerner, R. A., Benkovic, S. J., and Schultz, P. G. (1991) At the crossroads of chemistry and immunology: catalytic antibodies. Science 252, 659–667.PubMedCrossRefGoogle Scholar
  18. 18.
    Paul, S. (1996) Natural catalytic antibodies. Mol. Biotechnol. 5, 197–207.PubMedCrossRefGoogle Scholar
  19. 19.
    Li, L., Paul, S., Tyutyukova, S., Kazatchkine, M., and Kaveri, S. (1995) Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154, 3328–3332.PubMedGoogle Scholar
  20. 20.
    Paul, S., Volle, D. J., Beach, C. M., Johnson, D. R., Powell, M. J., and Massey, R. J. (1989) Catalytic hydrolysis of vasoactive intestinal peptide by human auto-antibody. Science 244, 1158–1162.PubMedCrossRefGoogle Scholar
  21. 21.
    Pauling, L. (1946) Molecular architecture and biological reactions. Chem. Eng. News 24, 1375–1377.CrossRefGoogle Scholar
  22. 22.
    Shuster, A. M., Gololobov, G. V., Kvashuk, O. A., Bogomolova, A. E., Smirnov, I. V., and Gabibov, A.G. (1992) DNA hydrolyzing autoantibodies. Science 256, 665–667.PubMedCrossRefGoogle Scholar
  23. 23.
    Yanase, K., Smith, R. M., Cizman, B., Foster, M. H., Peachey, L. D., Jarett, L., et al. (1994) A subgroup of murine monoclonal antideoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature-dependent manner. Lab. Invest. 71, 52–60.PubMedGoogle Scholar
  24. 24.
    Levinson, S. S. and Keren, D. F. (1994) Free light chains of immunoglobulins: clinical laboratory analysis. Clin. Chem. 40, 1869–1878.PubMedGoogle Scholar
  25. 25.
    Ioannidis, R. A., Joshua, D. E., Warburton, P. T., Francis, S. E., Brown, R. D., Gibson, J., et al. (1989) Multiple myeloma: evidence that light chains play an immunoregulatory role in B-cell regulation. Hematol. Pathol. 3, 169–175.PubMedGoogle Scholar
  26. 26.
    Maack, T., Johnson, V., Kau, S. T., Figueiredo, J., and Sigulem, D. (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16, 251–270.PubMedCrossRefGoogle Scholar
  27. 27.
    Carone, F. A., Peterson, D. R., Oparil, S., and Pullman, T. N. (1979) Renal tubular transport and catabolism of proteins and peptides. Kidney Int. 16, 271–278.PubMedCrossRefGoogle Scholar
  28. 28.
    Solomon, A., Weiss, D. H., and Kattine, A. A. (1991) Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845–1851.PubMedCrossRefGoogle Scholar
  29. 29.
    Dammacco, F. and Waidenstrom, J. (1968) Serum and urine light chain levels in benign monoclonal gammopathies, multiple myeloma and Waidenstrom’s macro-globulinemia. Clin. Exp. Immunol. 3, 911–921.PubMedGoogle Scholar
  30. 30.
    Nelson, M., Brown, R. D., Gibson, J., and Joshua, D. E. (1992) Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma. Br. J. Haematol. 81, 223–230.PubMedCrossRefGoogle Scholar
  31. 31.
    Sanders, P. W. (1994) Pathogenesis and treatment of myeloma kidney. J. Lab. Clin. Med. 124, 484–488.PubMedGoogle Scholar
  32. 32.
    Kyle, R. A. and Gertz, M. A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 32, 45–59.PubMedGoogle Scholar
  33. 33.
    Shirahama, T., Miura, K., Ju, S.-T., Kisilevsky, R., Grays, E., and Cohen, A. S. (1990) Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab. Invest. 62, 61–68.PubMedGoogle Scholar
  34. 34.
    Preud’homme, J.-L., Aucouturier, P., Touchard, G., Striker, L., Khamlichi, A. A., Rocca, A., et al. (1994) Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int. 46, 965–972.CrossRefGoogle Scholar
  35. 35.
    Huang, Z.-Q., Kirk, K. A., Connelly, K. G., and Sanders, P. W. (1993) Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 92, 2975–2983.PubMedCrossRefGoogle Scholar
  36. 36.
    De Fronzo, R. A., Cooke, C. R., Wright, J. R., and Humphrey, R. L. (1978) Renal function in patients with multiple myeloma. Medicine 57, 151–166.Google Scholar
  37. 37.
    Yokota, N., Yamamoto, Y., Kitamura, K., Kuroki, N., Hisanaga, S., Fujimoto, S., et al. (1991) Renal tubular lesions induced by human Bence Jones protein in the rat: N-acetyl-b-D-glucosaminidase as a sensitive marker. J. Exp. Pathol. 72, 255–262.Google Scholar
  38. 38.
    Fang, L. S. T. (1985) Light-chain nephropathy. Kidney Int. 27, 582–592.PubMedCrossRefGoogle Scholar
  39. 39.
    Ollerenshaw, S., Jarvis, D., Woolcock, A., Sullivan, C., and Scheibner, T. (1989) Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N. Engl. J. Med. 320, 1244–1248.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Hyogo Sinohara
  • Kinji Matsuura

There are no affiliations available

Personalised recommendations